Rainbow Rare Earths sees competitive advantage in new separation technology for Phalaborwa project. Watch the full video here.
Hi Dunk - in general that's right, but there were/are opportunities to speed up various regulatory stages of the trial and indeed to invest in treatments. Compared to investment/focus on vaccines and test and trace etc, the government focus on treatments is (or seems) negligible. Take the recent TILS application for inclusion in the therapies trial for example...not exactly fast track and why wasn't this progressed immediately after the Brazil trial anyway.
hi all - would be interested in views following the update.
Decent progress in lieu of the the product range, sales, expansion capacity and progress to sustainability, but Covid and exchange rates have impacted and of course there is ongoing uncertainty with regard to the former.
Just wondered if there were any particular points in the update that caught people's eyes (good or not so good)
and I'd like a bit of whatever ISATony was drinking...
Just got around to watching presentation - totally on board with Phase 2 expansion plans - got to prove the demand is there first and get toward the 30million extra sales which Phase 1 provides. They have reduced the expected cost of Phase 2 I note also. Onwards and upwards (towards Mr/Ms Tony's SP)
Thanks for replies..
I understand the wait and see approach, but I would have been happier if the board had the confidence to say they would instigate Phase 2 as soon as [whatever their criteria was] rather than place on back burner with the no plans in short or medium term. Investors would have wanted to know that the forecasted demand was there...and £4million was allocated to the Phase 2 expansion.
If cash burn based on last 6 months is circa 420k and they have £6.6 million minus £4million for expansion then we have £2.6 million available (which would last about 6 months). Of course, we anticipate increasing sales in this period (Hardman analyst talked of 30% uplift in H2) and the cash burn should drop each month. So I think we can reach profitability whilst maintaining the money for Phase 2 expansion which is good.
Also...From June 2020 RNS, £1.1. million was allocated to the Phase 1 expansion and would take 6 months. But they report it cost £2.1 million and RNS' show that it took a year (initiated June 2020, completion RNS 28 June 2021).
Curious - why do they report repeatedly that it was on budget (and on time) - with their own figures showing it cost twice as much and took twice as long (lol!). Sorry - I should have asked TRX in investor meet...but didn't make it.
RNS from June 2020...
'The Directors intend to use the net proceeds of the Fundraise as follows with approximately:
· £1.1 million towards the first phase of the Group's expansion programme to increase the manufacturing capacity in San Antonio to sustain future business growth, and general capital expenditure;
· £4.0 million towards the second phase of the Group's expansion programme to increase the manufacturing capacity in San Antonio to sustain future business growth;
· £1.9 million towards R&D and clinical, generating further clinical and health economic real-world data to support brand differentiation of dCELL® and BioRinse™ from competitive products; and
· £5.0 million towards general working capital to support the Company's growth.
It is envisaged that the first phase of the expansion programme will entail the addition of two sterile packaging clean rooms in the existing facility over a six month period. Once fully operational, these additional clean rooms are expected to increase the Group's current BioRinse processing capacity by c.50% and thereby significantly increase the maximum serviceable revenue for the BioRinse product portfolio. It is envisaged that phase two of the expansion programme will entail a further potential ten clean rooms, in the new facility adjacent to the current manufacturing site, expected to take approximately 12 months to complete. The Company intends to bring this new capacity on stream in a managed process to meet demand. Once fully operational, it is expected that this completed expansion programme will increase the Company's revenue generation potential by up to c.$36m per year'
Very happy re cost cutting while expanding. Running a tight ship, which is absolutely what is needed.
In a very good position now going forward to profitability. My only slight disappointment was re Phase 2 expansion - i.e. the implication that this is not needed in the short term (why not?). Was there any discussion of this in the investor talk? (which I will watch if it is available anywhere for a rerun?)
Re: results out tomorrow:
company investor webinar at 4.30pm - sign up at Investor meeet https://www.investormeetcompany.com/
the last one was really good.
RE questions - anyone know if you need to submit in advance? (if so, how) or can you do it live?
Given the Brazil trial results it is an international disgrace that not a single patient anywhere in the world has had a dose of Foralumab as a Covid treatment in 10 months- how many lives could have been saved! It's beyond comprehension that there was no clamour for further trials. Why are TILS even having to pay for the next trial - surely there should be grants for this sort of thing. How much money has been wasted on ineffective Innova LFTs and track and trace? I remain dumbfounded over this point. (it's not just in relation to TILS/Foralumab btw)
Its interesting that the SP is the same as 6 months ago.
I guess we need to see more/continued evidence that TRX is moving to profitability in the upcoming results, given there is not a huge amount of leeway re the cash runway.
We are pretty much at the prediction target I made last year for October, in the charity guess the share price game, but with the Phase 1 expansion having been delivered on time and on budget, and the new products, I'm very excited about this company prospects. More so than any other in my portfolio. Topped up today; as thinking we may see a rise into interims, or indeed subsequently - towards G&M target. Fingers crossed anyway. GLA
should have added the link to the hardman reports - https://www.hardmanandco.com/research/corporate-research/poised-for-growth/
While these are not independent, they do cover the fundamentals and the history.
Spotted a video from last month that I'd not seen before.
Tissue Regenix Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined *************. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance, share prices, key messages from the report and thoughts on what will happen to the shares.
Useful summary re the expansion of the company and the negative impact of collapse of Woodford fund, and Covid.
Headlines in line with the hardman report ..
TRX one of the few companies in World able to source raw tissue -and has increased its supply, and expansion at San Antonio means it has 3x storage tissue capacity, and additional clean rooms.
to get to where they are today, they have spent £103million...
Increased sales will not be seen in September...but expect to see 30%+ growth in second half of 2021...continuing in 2022.
I see the interim results as hugely significant given efforts to return to elective operations - just how successful has the return been in the key US market, and how have sales gone in this period. I remain optimistic here
I find it an odd concept for Zacks to predict the share price that far down the line given the dependencies. the reality is that if we any of the therapies progress well, then yes it should certainly be higher.
My main reason for investing has always been the potential in alzheimers of Foralumab. Loved what I heard and saw from Dr Weiner in the Bloomberg interview. Sounded like good progress on mouse models etc; I know we can criticise the interviews for their lack of specifics but they help to reassure me that these are GREAT world renowned scientists. That's who you want involved if you're in a pharmaceutical with potential, like TILS.
Worth a read re progress and developments.
Accoriding to the report...
Key reasons to own Tiziana shares:
? Multiple Phase II-ready assets pursuing unmet needs
o Fully human anti-CD3 - foralumab
? Multiple Sclerosis
? Crohn’s Disease
? COVID-19 / ARDS
o Pan-CDK inhibitor - milciclib
? Non-small cell lung carcinoma (NSCLC)
? Hepatocellular carcinoma (HCC)
o Fully human anti-IL-6 receptor – TZLS-501
? ARDS, ILD, COVID-19 and other diseases
? IND development underway
? Oral, nasal and inhaled administration of antibodies
o Improved ease of use
o No need for hospital-based infusion
o Lower doses required for efficacy
o Reduced systemic exposure and toxicity
o Fewer side effects with reduced systemic exposure and toxicity
o Focused distribution at the target organs in CD and severe lung disorders
o Higher lung drug retention and efficacy while minimising toxicity to other organs
? Validation of intranasal foralumab technology in Phase I COVID-19 trial
o Phase II trial announced
Their share target is $7.50 (currently $2.47).
I believe Tils have sposnored the report, although they state it is objective. Independent broker notes would be good going forward.
PS : AGM tomorrow
Plus - for those with HL or similar, note that the W-8BEN form may need to be reapplied for as only lasts a set period. I have just renewed mine.
Considering the likely outcome measures I agree that they could well drip feed results as they come through. So for example ventilation could be an outcome and on the basis of the former proof of mechanism study we could indeed have results very quickly; especially with 7 sites involved. The multi-site approach is the key to doing this quickly.